Vieira Aline Cristini, Megid Thais Baccili Cury, Melo Raissa, Muniz David, Salgues Alessandra Corte Real, Barbosa Felipe Galiza, Munhoz Rodrigo Ramella, Feher Olavo
Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
Radiology and Nuclear Medicine Service, Hospital Sírio-Libanês, São Paulo, Brazil.
Oxf Med Case Reports. 2020 Jan 31;2020(1):omz138. doi: 10.1093/omcr/omz138. eCollection 2020 Jan.
Dermal sarcomas represent a group or rare malignancies of mesenchymal origin. Although surgical excision with wide margins can be curative, in the advanced/metastatic setting, treatment options are limited and the benefit from anthracycline-based chemotherapy or targeted agents is usually short-lived. Tumor mutational burden and PD-L1 expression scores can be used as predictive biomarker for response to immunotherapy in some metastatic cancers. The role of immune-checkpoint blockade for sarcoma patients remains investigational. Here we present three cases of dermal sarcomas with high TMB and PD-L1 expression and responses to anti-PD1 agents in two of them.
皮肤肉瘤是一组起源于间充质的罕见恶性肿瘤。尽管广泛切缘的手术切除可以治愈，但在晚期/转移性情况下，治疗选择有限，基于蒽环类药物的化疗或靶向药物的获益通常是短暂的。肿瘤突变负荷和PD-L1表达评分可作为某些转移性癌症免疫治疗反应的预测生物标志物。免疫检查点阻断对肉瘤患者的作用仍在研究中。在此，我们报告三例高肿瘤突变负荷和PD-L1表达的皮肤肉瘤病例，其中两例对抗PD-1药物有反应。
